A New Era in Weight Loss Medication
The 7.2mg dose of Semaglutide is the highest licensed strength for weight loss and may help those who have reached a plateau on the 2.4mg dose. At PrivateDoc, we are monitoring this development closely to continue supporting patients with evidence-based treatment options.
“For many patients, reaching a plateau is disheartening — but it doesn’t mean progress has stopped,” explains Memoona Ali, Advanced Nurse Practitioner at PrivateDoc. “This higher Wegovy dose could offer another step forward for those who’ve responded well to Semaglutide but need a little more help to achieve their goals.”
How Wegovy 7.2mg Works
Wegovy (Semaglutide) is a GLP-1 receptor agonist that mimics a natural hormone regulating appetite, slows digestion, and helps reduce food cravings. The 7.2mg dose delivers a stronger effect for patients who’ve already used 2.4mg successfully but have reached a weight loss plateau.
Early trial data show patients taking Wegovy 7.2mg achieved an average 20.7% reduction in body weight, compared to 17.5% on the 2.4mg dose. These results are broadly comparable to Mounjaro (tirzepatide) 15mg.
Why This Matters for Patients
Weight loss journeys often involve periods where progress slows. The higher 7.2mg dose aims to overcome that barrier safely under medical supervision. PrivateDoc clinicians assess each patient individually, providing personalised guidance around nutrition, lifestyle, and wellbeing to ensure sustainable progress.
Risks and Side Effects — What to Know
While higher doses may deliver enhanced results, potential side effects remain. Common effects include nausea, vomiting, diarrhea, constipation, abdominal pain, and fatigue. Gradual titration under medical supervision is essential. Rare risks include pancreatitis, gallbladder issues, or thyroid tumours.
Availability in the UK
Wegovy 7.2mg has recently been licensed in the UK. Once available through PrivateDoc, patients will be able to discuss dose escalation safely with professional oversight via our online prescribing service.
Who Might Benefit?
- Patients who have lost weight on Wegovy 2.4mg but reached a plateau
- Those with minimal side effects on current doses
- Individuals seeking continued appetite control and motivation for lifestyle change
Some patients may not be suitable for dose escalation, including those with significant gastrointestinal side effects or contraindications. PrivateDoc ensures all treatment plans are clinically reviewed, prioritising safety and long-term outcomes.
PrivateDoc’s Approach to Safe, Supported Weight Management
- Medical review and personalised prescribing
- Lifestyle and nutrition guidance
- Regular check-ins through our online platform
- Monitoring for side effects and progress tracking
“Medication is just one part of the journey,” says Memoona Ali. “At PrivateDoc, we support every step — from managing appetite and metabolic health to maintaining confidence and wellbeing.”
Summary
The 7.2mg Wegovy dose represents a milestone in medical weight loss, potentially renewing results for patients who’ve plateaued on current doses. PrivateDoc will provide safe, regulated access once the medication is fully available, alongside personalised clinical support.
Suggested External References & Sources
- NICE TA875 — Semaglutide for managing overweight and obesity
- NICE NG246 — Obesity: identification, assessment and management (2025)
- MHRA / GOV.UK — GLP-1 medicines for weight loss and diabetes
- Society for Endocrinology (UK) — Joint position statement on medical therapies for obesity
Disclaimer
This article is for informational purposes only and is not a substitute for professional medical advice. Always consult a qualified healthcare professional before starting or changing any medication.
